LAVAL, QC, Nov. 24 /CNW/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company’s senior management team will discuss the product profile, clinical and regulatory progress and the market opportunity for its novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder.
